Active Ingredient History
Brincidofovir, sold under the brand name Tembexa, is an antiviral drug used to treat smallpox. Brincidofovir is a prodrug of cidofovir. Conjugated to a lipid, the compound is designed to release cidofovir intracellularly, allowing for higher intracellular and lower plasma concentrations of cidofovir, effectively increasing its activity against dsDNA viruses, as well as oral bioavailability. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Smallpox (approved 2021)
Adenoviridae (Phase 2)
Adenoviridae Infections (Phase 3)
Adenovirus Infections, Human (Phase 2)
BK Virus (Phase 2)
Cytomegalovirus Infections (Phase 3)
DNA Viruses (Phase 2/Phase 3)
Drug Interactions (Phase 1)
Ebolavirus (Phase 2)
Healthy Volunteers (Phase 1)
Hemorrhagic Fever, Ebola (Phase 2)
Infections (Phase 1/Phase 2)
Kidney Diseases (Phase 2)
Kidney Transplantation (Phase 3)
Liver Diseases (Phase 1)
Simplexvirus (Phase 1/Phase 2)
Smallpox (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue